

Ref. No.: WOCK/SEC/SE/2024-25/074

13th November, 2024

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
--	---

Dear Sir/ Madam,

Subject: Submission pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") - Press Release

Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release on the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2024.

A copy of the same will also be uploaded on the Company's website www.ockhardt.com

Kindly take the same on record please.

Thanking you,
For **Wockhardt Limited**

Rashmi Mamtura
Company Secretary

Encls: A/a

Mumbai, November 13th, 2024**H1FY25 EBITDA at Rs.239 crore; Growth by 112%**

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 2nd Quarter Results for Financial Year 2024-25, today.

Q2 REVENUE	Q2 EBITDA
818 Cr	139 Cr
↑ 7% Gr	↑ 71% Gr

• QoQ growth of 7% in revenue in Q2FY25, Revenue for Q2FY25 of INR 818 Cr compared to INR 762 Cr in the previous year. QoQ growth of 71% in EBITDA in Q2FY25, EBITDA for Q2FY25 of INR 139 Cr compared to INR 81 Cr in the previous year.

- YoY growth of 10% in revenue in H1FY25, Revenue for H1FY25 of INR 1,565 Cr compared to INR 1,420 Cr in the previous year. YoY growth of 112% in EBITDA in H1FY25, EBITDA for H1FY25 of INR 239 Cr compared to INR 113 Cr in the previous year.

H1 REVENUE	H1 EBITDA
1565 Cr	239 Cr
↑ 10% Gr	↑ 112% Gr

Novel Antibiotics:

ZAYNICH (WCK 5222): Global Phase III study is nearing completion. 99.5% enrolment has been completed. Global patient coverage is 528. Clinical Trial study progressing in 10 countries. We have treated 38 patients under compassionate usage, after approval of usage by DCGI. The product resulted in 100% cure and was found to be safe even when administered upto 60 days.

Global Patient Coverage 528 99.5% Enrolment Completed	 38 LIVES SAVED under Compassionate Use	 100% Success Rate	SAFE on Administration 60 Days
--	---	--	---

Meropenem Resistance Clinical Trial: DCGI has advised a Clinical Trial of 60 patients for which 100% patients have been recruited.

ZAYNICH successfully cures
A **RARE** case of **MENINGITIS**
caused by **MDR PSEUDOMONAS**
Critically ill Patient Cured in **4 weeks**

**CLSI Awards****64** mg/L**ZAYNICH****HIGH
SUSCEPTIBILITY
BREAKPOINTS****Meropenem Resistance Clinical Trial** | **100%** Patients Recruited (60)

Zaynich successfully treated a rare case of meningitis in a patient who was critically ill and had a drug-resistant infection. The patient was a 64-year-old man with hypertension and Type 2 diabetes who had been battling pulmonary and meningeal tuberculosis for about a year.

MIQNAF (WCK 4873):**MIQNAF (WCK 4873)**

COMMUNITY ACQUIRED BACTERIAL PNEUMONIA

FAVOURABLE RECOMMENDATION**FOR MANUFACTURING & MARKETING**

Central Drugs Standard Control Organisation

The Company has completed the pivotal Phase 3 pneumonia study of its antibiotic Nafithromycin WCK 4873 (MIQNAF) and has received favourable recommendation from Subject Expert Committee (SEC) of Central Drugs Standard Control

Organisation (CDSCO) for treatment of Community Acquired Bacterial Pneumonia (CABP).

The SEC recommendation is based on CDSCO's comprehensive review of product dossier consisting of non-clinical, US/EU Phase 1, Global Phase 2 and India Phase 3 clinical studies conducted over last 15 years. A positive opinion from SEC of CDSCO would pave the way for gaining DCGI's final approval for MIQNAF.

Wockhardt wins "BIRAC Innovator Award 2024"**Wockhardt wins "BIRAC Innovator Award 2024"****FOR SUCCESSFUL
DEVELOPMENT OF MIQNAF**

Company won the prestigious BIRAC INNOVATOR AWARD 2024 from the Government of India for the highest level of innovation and research that led to successful development of MIQNAF, the first ever Multi-Drug Resistant Pathogen active Respiratory antibiotic for the treatment of Community Acquired Bacterial Pneumonia.

It is after 30 years, that a new oral antibiotic, MIQNAF (WCK 4873) is going to be introduced shortly in India for Community Acquired Bacterial Pneumonia with a Success Rate of 97%.

This will meet a major antibiotic community need as existing drugs like Azithromycin has high resistance of 60%. It is only a three-day treatment, and it has eight times higher lung concentration than Azithromycin.

ZIDEACTAM (WCK 6777):




The Company's another breakthrough antibiotic once-a-day β -lactam enhancer, WCK 6777 with unique out-patient treatment advantage has been granted Fast Track designation by US FDA and has successfully completed Phase I study conducted by National Institutes of Health, US.

Additionally, recognizing its potential to meet significant unmet medical needs, the US FDA has recently granted Fast Track designation to WCK 6777 for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and complicated intra-abdominal infections (cIAI).

WCK 6777 is the only once-a-day drug in global antibiotic pipeline designed for outpatient-parenteral antimicrobial therapy (OPAT) in ambulatory settings. WCK 6777 is active against entire range of meropenem-resistant Gram negative pathogens generally encountered in community as well as hospital urinary tract infections (UTI) and intra-abdominal infections (IAI). Such a therapeutic option is expected to cut hospital admissions, facilitate early patient discharge and thus offer patient-centred care for MDR infections.

The promising safety data from this study paves the way for the advancement of WCK 6777 into Phase II / III clinical trials.

Biosimilars Business Highlights:




Our Insulin and Glargine business has demonstrated remarkable growth driven by increasing volumes across key markets such as Thailand, Algeria, Latin America and India. This robust expansion in emerging markets has been further fueled by strategic partnerships and new deal acquisitions, accelerating our presence and reach. In India, our domestic

biotech business is poised for substantial growth, leveraging a strong pricing advantage delivered by backward integrated manufacturing process. Additionally, our entry into new


markets including Russia, Malaysia, Brazil and Saudi Arabia positions us well for scaling the Biotech business growth to the next level. Looking ahead, the upcoming launch of insulin analogs in the coming quarters represents a significant business opportunity, further strengthening our commitment to meeting global diabetes healthcare needs and advancing our leadership in diabetes care.

Business Highlights


UK Business: Global Contribution in Q2 and H1 FY'25 is 37%



Emerging Markets Business: Global Contribution in Q2 FY'25 is 24%, H1 FY'25 is 26%



India Branded Business: Global Contribution in Q2 FY'25 is 15%, H1 FY'25 is 16%




Irish Business stood at Rs.43 crore in Q2FY25 and for H1FY25 the revenue was Rs.88 crore.

US Business stood at Rs.31 crore in Q2FY25 and Rs.60 crore in H1FY25 contributing 4% of the Global Revenue respectively.

New Products Launch:

- 2 Filings and 6 launches in H1FY25 in UK
- 1 Filing and 3 New launches in Ireland
- 1 New launch in US
- Registration has been filed in 10 countries of ROW for EMROK and EMROK O



Intellectual Property Update:

- 2 patents were filed during the quarter ended 30th September 2024 and the cumulative filings till date are 3267.
- The company was granted 1 patent during the quarter and now holds 843 patents.

PATENTS
Filings till Date : 3267
Patents Granted : 843

Financial Performance:

Particulars	Q2 FY25	Q2 FY24	Q1 FY25	H1FY25	H1FY24
	Jul - Sep 2024	Jul - Sep 2023	Apr - Jun 2024	Apr - Sep 2024	Apr - Sep 2023
Total Revenue	818	762	747	1,565	1,420
EBITDA before R&D	167	115	127	293	183
EBITDA % to Sales	20.4%	15.1%	16.9%	18.7%	12.9%
R&D	28	34	27	54	70
R&D % to Sales	3.4%	4.4%	3.6%	3.5%	4.9%
EBITDA	139	81	100	239	113
EBITDA Margins %	17.0%	10.7%	13.4%	15.3%	8.0%
Exceptional Items	-	-	-	-	(14)
PBT	(9)	(35)	(6)	(15)	(153)
Profit After Tax	(16)	(73)	(16)	(32)	(209)
PAT Margins %	-2.0%	-9.5%	-2.1%	-2.0%	-14.7%

PRESS RELEASE



Wockhardt Limited

Registered Office:
D-4, MIDC, Chikalthana
Chhatrapati Sambhajnagar
431006, India
Tel.: +91-22-2653 4444
CIN: L24230MH1999PLC120720

About Wockhardt

Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". It has a comprehensive Drug Discovery team and clinical organisation.



Wockhardt is employing around ~2600 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 79% of its global revenues coming from international businesses.